

bs-17166R**[Primary Antibody]****phospho-TPH2 (Ser19) Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn


techsupport@bioss.com.cn

400-901-9800

— DATASHEET —

Host: Rabbit	Isotype: IgG	Applications: IHC-P (1:100-500)
Clonality: Polyclonal		IHC-F (1:100-500)
GeneID: 121278	SWISS: Q8IWU9	IF (1:100-500)
Target: TPH2 (Ser19)		Reactivity: Rat (predicted: Human, Dog, Horse)
Immunogen: KLH conjugated synthesised phosphopeptide derived from human TPH2 around the phosphorylation site of Ser19: GF(p-S)LD.		
Purification: affinity purified by Protein A		Predicted MW.: 56 kDa
Concentration: 1mg/ml		Subcellular Location: Cytoplasm
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: Phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH) and tryptophan hydroxylase 2 (TPH2) comprise a small family of monooxygenases that catalyze the rate-limiting step in the catabolism of aromatic L-amino acids and utilize tetrahydropterine as a cofactor. TPH2 is highly expressed in the central nervous system (CNS), mainly in the brain. TPH2 catalyzes the first step in the biosynthesis of serotonin in the CNS and melatonin in the pineal gland, and may be involved in the pathology of several neuropsychiatric disorders. Glucocorticoid-mediated reduction of TPH2 is associated with the etiology of mood disorders, specifically psychotic major depression, and TPH2 may be related to dysregulation of serotonin neurotransmission in the brain which commonly leads to suicidal behavior.		

— VALIDATION IMAGES —



Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-phospho-TPH2(Ser19) Polyclonal Antibody, Unconjugated(bs-17166R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining